Watch Live

Tweet TWEET

Results from WEARIT-II Registry of Wearable Cardioverter Defibrillator Usage to Be Presented at Heart Rhythm 2013

  Results from WEARIT-II Registry of Wearable Cardioverter Defibrillator Usage
  to Be Presented at Heart Rhythm 2013

Heart Rhythm 2013 Booth #539

Business Wire

CHELMSFORD, Mass. -- April 29, 2013

ZOLL Medical Corporation, a manufacturer of medical devices and related
software solutions, announced today that results from the Prospective Registry
and Follow-Up of Patients Using the Wearable Defibrillator (WEARIT-II) will be
presented in a Late-Breaking Clinical Trial presentation at Heart Rhythm 2013,
the Heart Rhythm Society’s 34th Annual Scientific Sessions, Friday, May 10,
1:30-3:00 p.m., Session number SP22.

The 18-month results from WEARIT-II will be presented by Ilan Goldenberg, MD,
(Principal Investigator) University of Rochester Medical Center. WEARIT-II is
a prospective, observational study designed to evaluate high cardiac risk
patients’ clinical information, arrhythmias, and treatment findings during
wearable defibrillator use and subsequent one-year clinical course, including
survival.

“As an investigator in the original WEARIT/BIROAD clinical trial and the
co-principal investigator for the WEARIT-II Registry, it is rewarding to see
that these data will be shared as part of the Late-Breaking Clinical Trial
presentations at Heart Rhythm. The LifeVest^® plays an important role in the
continuum of care for patients at high risk from sudden cardiac arrest,” said
Arthur J. Moss, MD, University of Rochester Medical Center. “The LifeVest
allows physicians to protect patients during their period of highest risk
early after an acute cardiac event such as a myocardial infarction or newly
diagnosed nonischemic cardiomyopathy, when other therapies are not appropriate
due to the patient’s changing condition and the potential for cardiac
recovery.”

“WEARIT-II is the first multi-national registry of LifeVest usage and is
currently enrolling patients in the U.S., Europe, and Israel. We look forward
to this presentation of the 18-month U.S. results,” said Marshal Linder,
President of ZOLL LifeVest. “These data will add to our understanding of the
real-world treatment approaches and outcomes from physicians’ utilization of
wearable defibrillators.”

TheLifeVestWearable Defibrillator, along with sudden cardiac arrest (SCA)
education and screening tools, will be on display inBooth #539at Heart
Rhythm 2013 May 8-11 at the Colorado Convention Center in Denver.

LifeVest Provides Protection for Patients at Risk of SCA

The LifeVest Wearable Defibrillator protects patients at risk for sudden
cardiac arrest. It is used to protect a wide range of patients, including
patients with newly diagnosed heart failure, following recent myocardial
infarction, or following coronary revascularization. The LifeVest provides
protection during this period of high risk, gives physicians time to optimize
medical therapy, and helps ensure patients are not lost to follow up.

The LifeVest is lightweight and easy to wear, allowing patients to return to
their activities of daily living, while having the peace of mind that they are
protected from SCA. The LifeVest continuously monitors the patient’s heart
and, if a life-threatening heart rhythm is detected, the device delivers a
treatment shock to restore normal heart rhythm.

The LifeVest is covered by most health plans in the United States, including
commercial, state, and federal plans.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets
medical devices and software solutions that help advance emergency care and
save lives, while increasing clinical and operational efficiencies. With
products for defibrillation and monitoring, circulation and CPR feedback, data
management, fluid resuscitation, and therapeutic temperature management, ZOLL
provides a comprehensive set of technologies that help clinicians, EMS and
fire professionals, and lay rescuers treat victims needing resuscitation and
critical care. For more information, visitwww.zoll.com.

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding
company Asahi Kasei Corp., with operations in the chemicals and fibers, homes
and construction materials, electronics, and health care business sectors. Its
health care operations include devices and systems for critical care,
dialysis, therapeutic apheresis, transfusion, and manufacture of
biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and
nutritional products. With more than 25,000 employees around the world, the
Asahi Kasei Group serves customers in more than 100 countries. For more
information, visitwww.asahi-kasei.co.jp/asahi/en/.

Copyright © 2013 ZOLL Medical Corporation. All rights reserved. LifeVest and
ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in
the United States and/or other countries. All product names are the property
of their respective owners. Asahi Kasei is a registered trademark of Asahi
Kasei Corporation. All trademarks are the property of their respective owners.

Contact:

ZOLL Medical Corporation
Diane Egan, +1-978-421-9637
degan@zoll.com